Risk factors of furazolidone-associated fever.

Abstract

BACKGROUND:

Furazolidone is a synthetic nitrofuran with a broad spectrum of antimicrobial action and has been widely used in the treatment of Helicobacter pylori (H. pylori) infection. However, its safety profile has not been clarified. Moreover, the drug fever associated with its use is frequently misdiagnosed. The aim of this study was to explore the risk factors of furazolidone-associated fever to increase awareness and stimulate further research on this topic.

METHODS:

This was a retrospective case-control study of patients referred to a specialist clinic for furazolidone-containing quadruple regimens for H. pylori infection at a tertiary care hospital located in Eastern China between July 2018 and September 2018. We evaluated adult patients who received furazolidone treatment for Helicobacter pylori infection. The exclusion criteria were as follows: (1) patients were pregnant or breastfeeding; (2) patients received furazolidone treatment not for Helicobacter pylori infection; (3) patients had taken antibiotics or any acid suppressant or non-steroidal anti-inflammatory drug in the last 4 weeks; (4) patients had chronic hepatic, renal, or pulmonary disease. Pertinent information was retrieved from medical records and telephone follow-up. All statistical analysis was performed in SPSS version 22.0.

RESULTS:

A total of 1499 patients received furazolidone and met the overall inclusion criterion. Of these 1499 patients, 27 (1.80%) developed drug fever. The mean time between initiation of furazolidone and the onset of fever is 11.00 ± 1.84 days, and the median peak fever was 38.87 ± 0.57°C. We found no differences in age and past drug allergy between the non-fever and fever groups. Through multiple logistic regression analysis, we found two variables as independent risk factors for furazolidone-associated fever, including gender (OR, 3.16; 95% CI, 1.26-7.91; P = 0.014) and clarithromycin (OR, 4.83; 95% CI, 2.17-10.79; P<0.001).

CONCLUSIONS:

This retrospective cohort study identified two risk factors for furazolidone-associated fever, which were female and clarithromycin. We also analyzed the characteristics of drug fever during anti-Helicobacter pylori therapy. However, the underlying mechanisms are uncertain and require further research.

• Authors: Jiali Zhang, Chunling Rong, Chenyang Yan, Jie Chen, Wenjun Yang, Lingyan Yu, Haibin Dai
• Journal: PloS one (PLoS One) Vol. 17 Issue 4 Pg. e0266763 ( 2022) ISSN: 1932-6203 [Electronic] United States
• PMID: 35395029 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Furazolidone
• Amoxicillin
• Clarithromycin

Topics

• Adult
• Amoxicillin (therapeutic use)
• Anti-Bacterial Agents (adverse effects)
• Case-Control Studies
• Clarithromycin (therapeutic use)
• Drug Therapy, Combination
• Female
• Furazolidone (adverse effects)
• Helicobacter Infections (drug therapy, epidemiology)
• Helicobacter pylori
• Humans
• Retrospective Studies
• Risk Factors
• Treatment Outcome